Cheat sheet
Status: Not FDA-approved
Reviewed
KPV
A fragment of alpha-MSH that comes up constantly in inflammation and skin conversations. Here is what the research shows, and what it does not.
The evidence rail
How to read this- Mechanistic: reached
- Cell research: reached
- Animal research: reached
- Human observational: reached
- Human clinical trial: not reached
- Established clinical use: not reached
- Evidence
- Small human studiesRung 4 of 6. People were observed, surveyed, or followed, or given the peptide in a small study with no comparison group. Useful for patterns, silent on cause.
- Status
- Not FDA-approvedNot approved for use as a drug. Often sold as a research chemical.
What has it been studied for?
- Inflammation, including gut-adjacent questions
- Skin, in small human work
- Immune signaling around melanocortin pathways
What we know
- The name is in active conversation, including compounding news
- Human data exists and is limited
What we don’t
- Whether early signals hold in larger, well-controlled trials
- How to translate a study into a personal decision. That is a clinician's job, not ours
Bottom line
Promising is not proven. Read the paper.
Education only. Not medical advice. Not a protocol.
Keep reading
Related sheets
-
Gut / RecoveryBPC-157
Widely discussed for gut and recovery. The animal literature is large. Human clinical evidence is still thin.
-
Gut
Larazotide
One of the few names in this space with multiple human trials, studied around celiac and tight junctions.
-
Nerve / PainARA-290
Studied in nerve pain and inflammation. Small placebo-controlled trials exist. Large ones do not.
New sheets, the day they publish.
One email a week. The study type named, every time.